Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019.

Autor: Polkowska-Kramek A; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Begier E; Pfizer Inc, Dublin, Ireland., Bruyndonckx R; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Liang C; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA. caihua.liang@pfizer.com., Beese C; Pfizer Pharma GmbH, Berlin, Germany., Brestrich G; Pfizer Pharma GmbH, Berlin, Germany., Tran TMP; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Nuttens C; Pfizer Inc, Paris, France., Casas M; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Bayer LJ; Pfizer Pharma GmbH, Berlin, Germany., Huebbe B; Pfizer Pharma GmbH, Berlin, Germany., Ewnetu WB; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Agudelo JLR; P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium., Gessner BD; Pfizer Inc, 66 Hudson Blvd E, New York, NY, 10001, USA., von Eiff C; Pfizer Pharma GmbH, Berlin, Germany., Rohde G; Medical Clinic I, Department of Respiratory Medicine, Goethe University Frankfurt, University Hospital, Frankfurt/Main, Germany.

Publikováno v: Infectious diseases and therapy [Infect Dis Ther] 2024 Apr; Vol. 13 (4), pp. 845-860. Date of Electronic Publication: 2024 Mar 23.